Business Update
pSivida enters licensing negotiations with pharma company for drug delivery technologies
Published in Genetics and Environmental Business Week, January 25th, 2007
The pharmaceutical company will make payments totaling US$1.01 million (AUD 1.3 million) to pSivida for the right to exclusively negotiate a licensing agreement with the company for a period of 3 months and to fund the cost of a preclinical study. The preclinical study will focus on an evaluation of pSivida's drug delivery technologies in a very significant product opportunity.
...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genetics and Environmental Business Week
More Articles from Genetics and Environmental Business Week
- Biological Chemistry
Researchers from Memorial Sloan Kettering Cancer Center provide details of new studies and findings in the area of biological chemistry - Breast Cancer
Orion Genomics announces discovery, validation of breast cancer biomarkers - Business Update
454 sequencing reveals new class of small RNAs - Business Update
Clinical Data completes Vilazodone manufacturing technology transfer under license with Merck KGaA - Cancer Gene Therapy
Data on cancer gene therapy described by researchers at Memorial Sloan Kettering Cancer Center, Department of Surgery - Chronic Myelogenous Leukemia
Merck, Vertex initiate trial of Aurora kinase inhibitor in treatment-resistant leukemias - More from this issue of Genetics and Environmental Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
